PARP inhibitors and the treatment of breast cancer

Beyond BRCA1/2?

Kristine M. Frizzell, W. Lee Kraus

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2 In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice. These results suggest a potential broader utility of PARP-1 inhibitors in the treatment of breast cancer, although further mechanistic studies are needed.

Original languageEnglish (US)
Article number111
JournalBreast Cancer Research
Volume11
Issue number6
DOIs
StatePublished - Nov 26 2009

Fingerprint

Breast Neoplasms
Phenanthridines
Mutation
Cell Cycle Checkpoints
Heterografts
Ovarian Neoplasms
Cell Death
Growth
Poly(ADP-ribose) Polymerase Inhibitors
Neoplasms
Therapeutics
Poly (ADP-Ribose) Polymerase-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

PARP inhibitors and the treatment of breast cancer : Beyond BRCA1/2? / Frizzell, Kristine M.; Kraus, W. Lee.

In: Breast Cancer Research, Vol. 11, No. 6, 111, 26.11.2009.

Research output: Contribution to journalArticle

@article{ee326fbb804a4bfabf9f9a6d57259c7b,
title = "PARP inhibitors and the treatment of breast cancer: Beyond BRCA1/2?",
abstract = "Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2 In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice. These results suggest a potential broader utility of PARP-1 inhibitors in the treatment of breast cancer, although further mechanistic studies are needed.",
author = "Frizzell, {Kristine M.} and Kraus, {W. Lee}",
year = "2009",
month = "11",
day = "26",
doi = "10.1186/bcr2451",
language = "English (US)",
volume = "11",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - PARP inhibitors and the treatment of breast cancer

T2 - Beyond BRCA1/2?

AU - Frizzell, Kristine M.

AU - Kraus, W. Lee

PY - 2009/11/26

Y1 - 2009/11/26

N2 - Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2 In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice. These results suggest a potential broader utility of PARP-1 inhibitors in the treatment of breast cancer, although further mechanistic studies are needed.

AB - Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2 In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice. These results suggest a potential broader utility of PARP-1 inhibitors in the treatment of breast cancer, although further mechanistic studies are needed.

UR - http://www.scopus.com/inward/record.url?scp=77954581225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954581225&partnerID=8YFLogxK

U2 - 10.1186/bcr2451

DO - 10.1186/bcr2451

M3 - Article

VL - 11

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 6

M1 - 111

ER -